Experiments in diabetic mice and kidney cells suggest berberine may reduce renal glucose reabsorption and ease kidney damage through a FOXO1/SP1 signalling pathway, although human studies are still needed.
Berberine, a plant-derived compound long used in traditional Chinese medicine, may help protect the kidneys from diabetes-related damage by reducing a key glucose transporter in the kidney’s proximal tubules, according to a preclinical study published in Chinese Medicine.
Researchers used obese diabetic db/db mice and high-glucose-exposed human kidney-2 cells to examine whether the compound could influence sodium-glucose co-transporter 2, or SGLT-2, the protein that reabsorbs most of the glucose filtered by the kidneys. The study adds to earlier work suggesting berberine can lower blood sugar and support kidney function through several pathways, but it focuses on a more specific mechanism: a FOXO1/SP1 signalling axis linked to SGLT-2 expression.
In the animal experiments, berberine improved several signs of diabetic kidney injury. The treatment reduced blood glucose, improved glucose tolerance, lowered urinary albumin loss and eased markers of kidney dysfunction, while also softening structural damage seen under the microscope. The researchers also reported better renal filtration measures and less of the tissue injury associated with diabetic nephropathy. At the same time, the glucose-lowering effect did not rise in a simple dose-dependent pattern, suggesting berberine may act through multiple overlapping mechanisms rather than a single switch.
The mechanistic findings were centred on FOXO1, a transcription factor involved in metabolic regulation, and SP1, another protein that helps control gene activity. In diabetic mice and in kidney cells exposed to high glucose, berberine reduced FOXO1 activity, restored SP1 levels and suppressed SGLT-2. That change was accompanied by lower cellular glucose uptake. The authors also used docking simulations, thermal shift testing and gene-expression assays to support the idea that FOXO1 sits upstream of SP1 and SGLT-2 in this pathway, although they caution that these methods do not prove direct binding in living tissue.
The study went further by testing whether changing FOXO1 or SP1 altered berberine’s effect. When FOXO1 was overexpressed in kidney cells, berberine became less able to restore SP1 and suppress SGLT-2. Separately, blocking SP-family transcription factor activity weakened berberine’s impact. Those findings, together with evidence of physical association between FOXO1 and SP1, support the authors’ conclusion that berberine may curb renal glucose reabsorption by tuning this transcriptional network.
Still, the authors are careful not to overstate the results. The work was preclinical, so it cannot show whether the same pathway will produce the same benefit in people with diabetes. The researchers also note that some of the promoter studies were done in engineered cells rather than kidney tissue itself, and they say further experiments are needed to confirm how FOXO1 and SP1 behave in the kidney. They also flagged a possible safety question: combining berberine with empagliflozin, an established SGLT-2 inhibitor, improved metabolic and renal outcomes, but there was a rise in aspartate aminotransferase, or AST, that warrants more investigation before any claim of added benefit can be made.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
